Shift from surrogate end point to outcome trials: implications for cardiovascular safety assessment in development programs for antidiabetic drugs. (Q51173466)
Jump to navigation
Jump to search
scientific article published on 23 November 2011
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Shift from surrogate end point to outcome trials: implications for cardiovascular safety assessment in development programs for antidiabetic drugs. |
scientific article published on 23 November 2011 |
Statements
Shift from surrogate end point to outcome trials: implications for cardiovascular safety assessment in development programs for antidiabetic drugs. (English)
1 reference
J F Marcinak
1 reference
P Viswanathan
1 reference
V Arora
1 reference
L E Roebel
1 reference
T R Strack
1 reference
E Leifke
1 reference
23 November 2011
1 reference
91
1 reference
3
1 reference
514-520
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference